Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 62.52B 9.31B 8.06B 7.63B 6.9B 12.96B 893B 13.05B 91B 35.01B 453B 34.97B 34.2B 1,444B P/E 2026 *
47.2x
P/E 2027 * 35.6x
Enterprise Value 57.85B 8.61B 7.46B 7.06B 6.39B 11.99B 826B 12.08B 84.2B 32.39B 419B 32.36B 31.64B 1,336B EV / Sales 2026 *
7.15x
EV / Sales 2027 * 6x
Free-Float
61.13%
Yield 2026 *
0.76%
Yield 2027 * 1.02%
Manager TitleAgeSince
Chief Executive Officer 70 06/10/1998
Chief Executive Officer 49 18/01/2022
President - -
Director TitleAgeSince
Director/Board Member 49 17/07/2011
Chairman 70 06/10/1998
Director/Board Member 65 17/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.31B
-0.19%+1.09%+51.85%+97.36% 1,013B
+0.33%-0.71%+50.62%+65.50% 644B
+0.49%+5.73%+20.88%+72.92% 465B
-0.22%+2.88%+38.48%+37.98% 352B
-0.07%+1.82%+16.57%+23.39% 264B
-0.31%+2.02%+6.15%+10.75% 253B
-1.53%-4.46%+36.90%+44.08% 203B
-1.60%-5.51%-22.30%-58.60% 188B
+0.49%-0.23%+30.00%+93.34% 181B
Average -0.07%-1.08%+25.46%+42.97% 395.97B
Weighted average by Cap. +0.40%+0.01%+34.52%+59.42%

Financials

2026 *2027 *
Net sales 8.09B 1.2B 1.04B 987M 893M 1.68B 116B 1.69B 11.77B 4.53B 58.59B 4.52B 4.42B 187B 9.8B 1.46B 1.26B 1.2B 1.08B 2.03B 140B 2.05B 14.27B 5.49B 71B 5.48B 5.36B 226B
Net income 1.41B 210M 182M 172M 156M 293M 20.17B 295M 2.05B 791M 10.23B 790M 772M 32.61B 1.82B 271M 234M 222M 201M 377M 25.96B 380M 2.65B 1.02B 13.16B 1.02B 994M 41.98B
Net Debt -4.67B -696M -603M -570M -516M -969M -66.76B -976M -6.8B -2.62B -33.85B -2.61B -2.56B -108B -3.66B -544M -472M -446M -404M -758M -52.22B -763M -5.32B -2.05B -26.48B -2.04B -2B -84.45B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!